ZBH Financials Zimmer Biomet

15 years of revenue, profit, cash flow and balance-sheet history through FY2025, from SEC filings — with a computed, factual read of the trend. Updated 28 h ago Overview →

Growth & profitability

Revenue has grown 6.1% per year over the past 5 years.
Operating margin has expanded, at 13.3% in the latest year.
Free cash flow has grown 6.2% per year over the past 5 years.

Financial health

Total debt ($7.5B) exceeds cash ($592M); net debt is $6.9B.
Total debt has grown slower than revenue (-1.5% vs 6.1% per year).
Total debt is 3.4× EBITDA.

Shareholder returns

Dividends have been paid for 14 consecutive years, consuming 27.0% of earnings and 12.9% of free cash flow.
The dividend has declined 0.8% per year over the past 5 years.

Revenue & net income

RevenueNet income

Margins (gross / operating / net)

GrossOperatingNet

Free cash flow (CFO − capex)

Free cash flow

Cash vs total debt

CashTotal debt

Cash flow: operating / investing / financing

OperatingInvestingFinancing

Key annual figures

FY	Revenue	Net income	Gross M	Op M	FCF	Total debt	Cash
2025	$8.2B	$705M	69.7%	13.3%	$1.5B	$7.5B	$592M
2024	$7.7B	$904M	71.5%	16.7%	$1.3B	$6.2B	$526M
2023	$7.4B	$1.0B	71.8%	17.3%	$1.3B	$5.8B	$416M
2022	$6.9B	$231M	70.9%	10.0%	—	$5.7B	$376M
2021	$6.8B	$402M	71.3%	12.6%	$1.4B	$7.1B	$378M
2020	$6.1B	-$139M	70.2%	1.4%	$1.1B	$8.1B	$775M
2019	$7.0B	$1.1B	72.1%	16.0%	$1.4B	$8.2B	$618M
2018	$7.9B	-$379M	71.4%	0.4%	$1.6B	$8.9B	$543M
2017	$7.8B	$1.8B	72.7%	10.2%	$1.4B	$10.1B	$524M
2016	$7.7B	$306M	68.9%	10.7%	$1.4B	$11.2B	$634M
2015	—	$147M	—	—	—	$11.5B	$1.5B
2014	—	$720M	—	—	—	$1.4B	$1.1B
2013	—	$780M	—	—	$863M	$1.7B	$1.1B
2012	—	$755M	—	—	$1.0B	$1.8B	$884M
2011	—	$761M	—	—	$1.1B	$1.7B	$768M

Revenue & net income

RevenueNet income

Margins (gross / operating / net)

GrossOperatingNet

Free cash flow (CFO − capex, quarterly)

Free cash flow

Cash vs total debt

CashTotal debt

Cash flow: operating / investing / financing

OperatingInvestingFinancing

Key quarterly figures

Quarter	Revenue	Net income	Gross M	Op M	FCF	Total debt	Cash
Mar '26	$2.1B	$238M	72.4%	17.9%	$323M	$7.5B	$424M
Dec '25	$2.2B	$139M	64.7%	6.9%	$443M	$7.5B	$592M
Sep '25	$2.0B	$231M	72.1%	17.6%	$364M	$8.1B	$1.3B
Jun '25	$2.1B	$153M	71.5%	14.4%	$328M	$7.6B	$557M
Mar '25	$1.9B	$182M	71.2%	15.3%	$338M	$7.2B	$1.4B
Dec '24	$2.0B	$240M	71.0%	19.2%	$455M	$6.2B	$526M
Sep '24	$1.8B	$249M	70.5%	15.3%	$351M	$6.5B	$569M
Jun '24	$1.9B	$243M	71.5%	18.1%	$317M	$5.8B	$420M
Mar '24	$1.9B	$172M	72.9%	14.1%	$173M	$5.8B	$393M
Dec '23	$1.9B	$419M	72.2%	18.3%	—	$5.8B	$416M
Sep '23	$1.8B	$163M	70.4%	15.2%	$253M	$5.5B	$292M
Jun '23	$1.9B	$210M	71.9%	17.6%	$251M	$5.7B	$320M
Mar '23	$1.8B	$233M	72.6%	17.9%	$261M	$5.8B	$330M
Dec '22	$1.8B	-$131M	71.5%	-1.6%	—	$5.7B	$376M
Sep '22	$1.7B	$194M	70.8%	14.7%	—	$5.7B	$545M
Jun '22	$1.8B	$154M	71.3%	15.8%	—	$6.0B	$386M
Mar '22	$1.7B	$14M	69.9%	11.9%	—	$6.3B	$436M
Dec '21	$1.8B	-$84M	69.8%	7.5%	$317M	$7.1B	$378M
Sep '21	$1.7B	$146M	70.8%	14.4%	$389M	$7.5B	$920M
Jun '21	$1.8B	$142M	71.9%	12.7%	$429M	$7.9B	$1.0B

Valuation over time

How the market has priced ZBH against its own fundamentals since 2023-03 — each month-end's share price set against the most recent annual filing, so the multiple moves as price runs ahead of (or behind) earnings. Split-adjusted.

The price-to-earnings ratio has fallen from 108.0× (Mar '23) to 25.0× (Jun '26).
The price-to-sales ratio has fallen from 3.6× (Mar '23) to 2.1× (Jun '26).
The dividend yield has risen from 0.8% (Mar '23) to 1.1% (Jun '26).

Price / earnings (P/E)

P/E

Price / sales (P/S)

P/S

Dividend yield (%)

Dividend yield %

Frequently asked questions

Is ZBH growing its revenue and profit?

Over the past 5 years, Zimmer Biomet's revenue has grown 6.1% per year. These are computed facts, not advice.

How much debt does ZBH have?

As of FY2025, Zimmer Biomet reported $7.5B of total debt against $592M of cash.

What is ZBH's profit margin?

In FY2025, gross margin was 69.7%, operating margin 13.3%, and net margin 8.6%.

What is ZBH's P/E ratio?

As of Jun '26, Zimmer Biomet traded at a price-to-earnings ratio of about 25.0× (market cap ÷ latest annual net income). The valuation charts above show how its P/E, P/S and dividend yield have moved with the share price. These are computed facts, not advice.

Where does this data come from?

All figures are extracted from the company’s SEC EDGAR/XBRL filings — 10-K annual reports and 10-Q quarterly reports (use the Annual / Quarterly toggle). Quarterly figures are derived from the as-filed statements (year-to-date amounts are differenced into discrete quarters). Growth rates and ratios are computed by tradmap; nothing here is investment advice.

Source: SEC EDGAR / XBRL (10-K + 10-Q filings) · prices EOD (Databento), corporate-action-adjusted · growth rates, valuation multiples & ratios computed by tradmap. Valuation uses each month-end price against the latest annual filing. Informational only — not investment advice.